scholarly journals Urinary Vascular Cell Adhesion Molecule, But Not Neutrophil Gelatinase-associated Lipocalin, Is Associated with Lupus Nephritis

2012 ◽  
Vol 39 (6) ◽  
pp. 1231-1237 ◽  
Author(s):  
ADNAN N. KIANI ◽  
TIANFU WU ◽  
HONG FANG ◽  
XIN J. ZHOU ◽  
CHUL W. AHN ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Lupus Nephritis ◽  
Disease Activity ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Vascular Cell Adhesion ◽  
Systemic Lupus ◽  
Vascular Cell ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Neutrophil Gelatinase

Objective.Vascular cell adhesion molecule-1 (VCAM-1), an adhesion molecule, is involved in the progression of glomerular and tubulointerstitial injury. Neutrophil gelatinase-associated lipocalin (NGAL), a member of the lipocalin superfamily, has been shown to rise in both acute and chronic kidney damage. Both VCAM-1 and NGAL have been found at high levels in the urine of patients with active lupus nephritis. We investigated both as potential biomarkers for lupus nephritis.Methods.VCAM-1 and NGAL were measured by ELISA during 1 to 8 clinic visits in 107 patients with systemic lupus erythematosus (SLE; 91% women, 51% black, 36% white, 4% Asian, 4% Hispanic, and 5% others) for a total of 190 visits. Patients’ mean age was 41 years. We analyzed the relationship between these potential urine biomarkers and the urine protein/creatinine ratio (urine Pr/Cr), the Systemic Lupus International Collaborating Clinics (SLICC) renal activity score, SLE Disease Activity Index renal descriptors, and other clinical variables.Results.VCAM-1 levels were strongly associated with the physician’s global estimate of disease activity (p = 0.0002), the renal visual analog scale (p < 0.0001), the urine Pr/Cr (p < 0.0001), and SLICC renal activity score (p < 0.0001). VCAM-1 levels were also associated with a urine Pr/Cr ≥ 0.5 (p < 0.0001). NGAL was not associated with any measure of disease activity or with lupus serologies.Conclusion.Urine VCAM-1 had a strong association with measures of disease activity, including multiple renal activity descriptors. In contrast to previous SLE studies, NGAL failed to show any association with lupus nephritis.

Elevated Urinary and Blood Vascular Cell Adhesion Molecule-1 as Potential Biomarkers for Active Systemic Lupus Erythematosus: A Meta-analysis

2020 ◽  
Vol 26 (46) ◽  
pp. 5998-6006
Author(s):  
Yuan-Rui Xia ◽  
Yan-Mei Mao ◽  
Jun-Ping Wang ◽  
Qing-Ru Li ◽  
Yin-Guang Fan ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Cell Adhesion ◽  
Disease Activity ◽  
Adhesion Molecule ◽  
Lupus Erythematosus ◽  
Cell Adhesion Molecule ◽  
Vascular Cell Adhesion ◽  
Systemic Lupus ◽  
Vascular Cell ◽  
Cell Adhesion Molecule 1

Objective: Due to the inconsistent results of current studies on the association between urinary and blood vascular cell adhesion molecule-1 (VCAM-1) and systemic lupus erythematosus (SLE) disease activity, we conducted this study and analyzed its influencing factors. Methods: A literature search was conducted in PubMed, EMBASE, Web of Science, and Cochrane Library. Data were extracted from eligible studies to calculate standardized mean differences (SMD) with 95% confidence intervals (CI). Cochrane Q test and I2 statistics were used to examine heterogeneity. The sources of heterogeneity were assessed through sensitivity analysis and subgroup analysis. Publication bias was evaluated by funnel plots and Egger's test. Results: A total of 15 studies met the inclusion criteria, including 473 active SLE patients and 674 inactive SLE patients. The random effects model was used for data analysis. In both urine and blood samples, VCAM- 1 level in active SLE patients was significantly higher than those in inactive SLE patients (urine: SMD: 0.769; 95% CI: 0.260-1.278; blood: SMD=0.655, 95% CI: 0.084-1.226). No publication bias was found in this study. Conclusion: Compared with inactive SLE patients, patients with active SLE have higher levels of VCAM-1 in both urine and blood. VCAM-1 may be a potential indicator of SLE disease activity.

scholarly journals POS0341 sVCAM-1 EXPRESSION IN TAKAYASU ARTERITIS TREATED WITH TOCILIZUMAB: A PROSPECTIVE PILOT STUDY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 398.2-399
Author(s):  
S. Ackermann ◽  
P. Villiger ◽  
A. Gloor ◽  
K. K. Eriksson ◽  
M. Seidel
Keyword(s):  
Cell Adhesion ◽  
Pilot Study ◽  
Disease Activity ◽  
Adhesion Molecule ◽  
Takayasu Arteritis ◽  
Vessel Wall ◽  
Cell Adhesion Molecule ◽  
Vascular Cell Adhesion ◽  
Vascular Cell ◽  
Cell Adhesion Molecule 1

Background:Takayasu arteritis (TA) is a rare disease, its diagnosis is often delayed by years. Biomarkers might be helpful for earlier diagnosis and for monitoring treatment. We have described serum soluble vascular cell adhesion molecule-1 (sVCAM-1) as a marker of inflammation in a variety of rheumatic diseases, including vasculitis (1). Tocilizumab (TCZ) is a monoclonal antibody against the interleukin-6 receptor with established benefits in TA (2). It may spare oral glucocorticoids (GC) and Disease-Modifying Agents (DMARDs). So far, sVCAM-1 has never been examined as diagnostic marker or to monitor disease activity in TA patients treated with TCZ.Objectives:To analyze sVCAM-1 in TA patients treated with TCZ in a prospective clinical trial and compare these results to age-matched healthy controls (HC) as well as DMARDs. In addition, MRI analyses of aortic wall thickening and enhancement might serve as a morphologic correlate of serologic disease activity.Methods:29 TA patients were prospectively followed between 2016 and 2019 (27 females, mean ± SD: 39.2±13.9 years) at the Department of Rheumatology of the University Hospital of Bern, Switzerland. At baseline, patients were without treatment (n=8) or treated with TCZ (n=13), GC (n=4), GC + methotrexate (MTX) (n=1), infliximab (IFX) + MTX (n=1), GC + IFX (n=1), MTX (n=1). Three follow-ups were performed after an average of 12, 24, 34 ± 3 months. sVCAM-1 was measured in serum using a commercially available ELISA kit (R&D Systems, Germany). Results were compared to 29 sera of matched HC (27 females, 40.8±15.1 years). MRI of aortic changes were scored on a scale of 0 (no thickening and vessel wall enhancement) to 3 (maximal thickening and vessel wall enhancement). Cumulated sVCAM-1 concentrations from each MRI scoring group (0-3) were compared to HC in order to determine if sVCAM-1 from high aortic MRI inflammation was significantly elevated.Results:At baseline, significantly increased serum concentrations of sVCAM-1 (ng/ml) were observed in TA patients without treatment (n=8, 537.3±130.1, p=0.002) vs. HC (336.0±76.1). A smaller difference was found between patients under treatment and HC (n=21, 468.2±105.3 vs. 405.1±82.5, p=0.04). Follow-ups in the TCZ group showed 518.9±138.9 vs. 417.5±46, p=0.12 (n=6) after 12 months, 436.6±77.3 vs. 399.6±113.1, p=0.46 (n=8) after 24 months and 407.1±27.1 vs. 381.8±60.4, p=0.47 (n=4) after 36 months. In contrast, patients under DMARD therapy showed values of 505.8±126.4 vs. 395.6±60.2 p=0.04 (n=8) after 12 months, 437.8±76.2 vs. 396.4±91.9, p=0.24 (n=12) after 24 months and 440±43.3 vs. 323±50 p=0.03 (n=8) after 36 months. MRI analyses showed that group 0 (no inflammation, n=7) had significant increased values compared to HC (474.7±106.8 vs. 356.9±48.8, p=0.02), and group 3 (maximal inflammation, n=11) was also elevated (461.8±98.4 vs. 379.3±88.9, p=0.05).Conclusion:The results suggest that sVCAM-1 is a biomarker of disease activity in patients with TA. The results at follow-up show that sVCAM-1 decreased more rapidly under treatment with TCZ compared to treatment with DMARDs. Remarkably, sVCAM-1 concentrations did not correlate with disease activity as assessed with MRI.References:[1]Oleszowsky M, Seidel MF. Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study. BioMed Res Int. 2018;8286067.[2]Hellmich B, Agueda A, Monti S, Buttgereit F, Boysson H de, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020 Jan 1;79(1):19–30.Disclosure of Interests:None declared

Relationship between serum vascular cell adhesion molecule-1 and endothelin-1 levels with organ involvement and disease activity in systemic lupus erythematosus patients

Lupus ◽  
2018 ◽  
Vol 27 (12) ◽  
pp. 1918-1925
Author(s):  
M Hajialilo ◽  
P Tayari ◽  
A Ghorbanihaghjo ◽  
A Khabbazi ◽  
A Malek Mahdavi ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Disease Activity ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Organ Involvement ◽  
Vascular Cell Adhesion ◽  
Vascular Cell ◽  
Vascular Cell Adhesion Molecule ◽  
Endothelin 1 ◽  
Cell Adhesion Molecule 1

Background Endothelial dysfunction plays an important role in pathogenesis of systemic lupus erythematosus (SLE). Considering the importance of serum soluble vascular cell adhesion molecule-1 as the most abundant of the circulating adhesion molecules increased as a result of endothelial dysfunction and the role of endothelin-1 in pathophysiology of SLE, this study aimed to evaluate serum soluble vascular cell adhesion molecule-1 and endothelin-1 levels in SLE patients compared to healthy subjects. Methods In this cross-sectional study, 60 SLE patients according to the Systemic Lupus International Collaborating Clinics classification criteria for SLE and 40 age and sex-matched healthy controls were included. In patients, clinical examination was performed and SLE disease activity index was assessed. Serum endothelin-1 and soluble vascular cell adhesion molecule-1 levels were measured using ELISA kits. Results The mean ± standard deviation age of patients and controls was 31.91 ± 7.66 and 33.20 ± 10.08 years, respectively. Compared to healthy controls, serum soluble vascular cell adhesion molecule-1 (1023.8 ± 352.96 vs. 866.06 ± 109.91) and endothelin-1 (77.83 ± 16.27 vs. 54.45 ± 12.01) was significantly higher in SLE patients ( P = 0.003 and P < 0.001, respectively). The most common organs involved in patients were skin, joint and kidney. There were no significant differences in serum soluble vascular cell adhesion molecule-1 and endothelin-1 levels according to organ involvement, activity of disease and the conventional serum markers of disease activity ( P > 0.05). There was no significant correlation between disease activity, organ involvement and negative or positivity of autoantibodies as well as serum complement with endothelin-1 and vascular cell adhesion molecule-1 levels ( P > 0.05). Conclusions Although our study revealed higher serum soluble vascular cell adhesion molecule-1 and endothelin-1 levels in SLE patients compared to healthy controls, there were no significant correlations between their serum levels with organ involvement and disease activity.

Urinary biomarkers for lupus nephritis: the role of the vascular cell adhesion molecule-1

Lupus ◽  
2019 ◽  
Vol 28 (3) ◽  
pp. 265-272 ◽  
Author(s):  
A A Gasparin ◽  
N Pamplona Bueno de Andrade ◽  
V Hax ◽  
G Leví Tres ◽  
F V Veronese ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Lupus Nephritis ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Urinary Biomarkers ◽  
Vascular Cell Adhesion ◽  
Vascular Cell ◽  
Vascular Cell Adhesion Molecule ◽  
Renal Histology ◽  
Cell Adhesion Molecule 1

Renal involvement is one of the main complications of systemic lupus erythematosus, causing a significant impact on patients' morbidity and mortality. Renal biopsy is still the gold standard of diagnosis, but it has many limitations. In this sense, several recent studies aim to identify biomarkers that not only predict disease activity and renal histology, but also lead to earlier treatment. In previous studies, the soluble vascular cell adhesion molecule-1 measured in urine showed a strong association with the presence of lupus nephritis, with clinical and histological activity indexes of the disease and with more severe renal lesions. This paper reviews the main urinary biomarkers of lupus nephritis that have been studied, with special emphasis on vascular cell adhesion molecule-1 results.

Sign in / Sign up

Export Citation Format

Share Document